151
Participants
Start Date
October 26, 2020
Primary Completion Date
June 5, 2023
Study Completion Date
June 5, 2023
18F fluciclovine
18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
NYU Langone Health, New York
University of Pennsylvania Health System, Philadelphia
Johns Hopkins Hospital, Baltimore
West Virgina University Cancer Institute, Morgantown
Medical College of Georgia, Augusta University, Augusta
Miami Cancer Institute at Baptist Health, Inc., Miami
University of Alabama at Birmingham, Birmingham
University Hospital Cleveland, Cleveland
Cleveland Clinic, Cleveland
University of Michigan Rogel Cancer Center, Ann Arbor
Henry Ford Hospital, Detroit
Washington University School of Medicine-Center for Clinical Imaging Research, St Louis
Ochsner Clinic Foundation, New Orleans
The University of Texas MD Anderson Cancer Center, Houston
Center for Quantitative Cancer Imaging at Huntsman Cancer Institute, Salt Lake City
St. Joseph's Hospital and Medical Center, Phoenix
John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica
University of California, San Francisco, San Francisco
Yale School of Medicine, New Haven
Lead Sponsor
Collaborators (1)
Precision For Medicine
INDUSTRY
Blue Earth Diagnostics
INDUSTRY